BPA Biosante Pharmaceuticals

BioSante Pharmaceuticals (AMEX: BPA) today announced that Stephen M. Simes, president and chief executive officer, will present a corporate overview at three upcoming conferences. The conferences are: The Annual Sachs North American Forum for Investing and Partnering in Biotech and Medtech on March 12, 2007 at 11:55 a.m. EDT at the Fairmont Copley Plaza in Boston. The Arch Investment Conference on March 21, 2007 at 1:30 p.m. EDT at the St. Regis Hotel in New York City. The Wall Street Reporter Small-Cap Discovery Conference on March 22, 2007 at 9:00 a.m. EDT at the Princeton Club of New York. A live audio webcast of BioSante�s presentation at these conferences can be accessed on the internet by visiting www.biosantepharma.com. An archive of these presentations will be available at the same address. About BioSante Pharmaceuticals, Inc. BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver bio-identical estradiol and testosterone. BioSante's lead products include Elestrin� (estradiol gel), developed through FDA approval by BioSante, indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and LibiGel� (transdermal testosterone gel) in Phase III development for the treatment of female sexual dysfunction (FSD). The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion. The transdermal gel formulations used in the women's gel products are licensed by BioSante from Antares Pharma. The company also is developing its calcium phosphate nanotechnology (CaP) for novel vaccines, including hepatitis B, avian flu and biodefense vaccines for toxins such as anthrax, as well as a system for delivering drugs via alternative routes of administration. Additional information is available online at www.biosantepharma.com.